1001-00004 · Ardent Capital Partners · Antitrust & Regulatory

remedies-divestiture-analysis-memo.docx DOCUMENT M&A / Corporate

10 / 78 ← → ✕

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

CALDERWOOD & HARKNESS LLP 7 Times Square New York, NY 10036

INTERNAL MEMORANDUM

Matter No.: 1001-00004

Date: April 14, 2025

To: James Prentice, Esq. (Responsible Partner, Mergers & Acquisitions) Sandra Tung, Esq. (Billing Partner, Mergers & Acquisitions)

From: Elaine Forsythe, Esq. (Specialist Partner, Antitrust & Competition) Ryan Kowalski, Esq. (Lead Associate, Mergers & Acquisitions) Megan Chu, Esq. (Working Associate, Mergers & Acquisitions)

Re: Remedies and Divestiture Analysis — Competitive Overlap Between Luminex Systems Holdings Inc. and Vectis Solutions LLC in Procurement-Automation SaaS

PRIVILEGE NOTICE: This memorandum is protected by the attorney-client privilege and the work-product doctrine. It has been prepared by attorneys at Calderwood & Harkness LLP in connection with the pending acquisition of Luminex Systems Holdings Inc. by Ardent Apex Holdings Inc. / Ardent Capital Partners III LP and reflects confidential legal analysis, mental impressions, conclusions, and strategic recommendations of counsel. This memorandum is not to be distributed, disclosed, or otherwise made available to any person or entity outside of Calderwood & Harkness LLP without the prior written approval of James Prentice or Elaine Forsythe. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.

Right-click to update Table of Contents

I. Executive Summary

This memorandum analyzes the potential remedies that the Federal Trade Commission ("FTC") may require to address the horizontal competitive overlap arising from Ardent Capital Partners III LP's ("Fund III") simultaneous ownership — through its sponsor group's affiliated funds — of Vectis Solutions LLC ("Vectis"), an existing portfolio company of Ardent Capital Partners II LP ("Fund II"), and Luminex Systems Holdings Inc. ("Luminex" or the "Target"), the target of the pending $2,800,000,000 reverse triangular merger (the "Transaction"). The overlap between these two businesses in the procurement-automation software-as-a-service ("SaaS") market is the central competitive concern and the focus of this analysis.

The core antitrust concern is straightforward: Following the closing of the Transaction, the Ardent fund family — through the common management and governance of Ardent Capital GP III LLC and Ardent Capital GP II LLC — would exercise control over two significant competitors in the procurement-automation SaaS market. Luminex holds an estimated market share of approximately 18%, and Vectis holds an estimated market share of approximately 7%, resulting in a combined post-acquisition market share of approximately 25%. While this combined share does not automatically trigger the structural presumption under the 2023 FTC/DOJ Merger Guidelines (which generally applies at a 30% threshold), it falls squarely within the zone of heightened FTC scrutiny, particularly in light of the current Commission's aggressive enforcement posture toward private equity roll-ups and serial acquisitions in technology markets.

Regulatory status. The parties filed their pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") on March 28, 2025 (Transaction No. HSR-20250328-4192). The filing was allocated to the FTC by the Department of Justice Antitrust Division on April 2, 2025, and the initial 30-day waiting period is set to expire on April 27, 2025. Based on preliminary staff inquiries received during the first two weeks following the filing, as well as the nature and magnitude of the competitive overlap, we anticipate that the FTC will issue a Request for Additional Information and Documentary Material (a "Second Request") on or about April 25, 2025. The issuance of a Second Request would extend the waiting period and trigger a substantially more intensive investigation.

Remedy pathways. This memorandum evaluates three principal remedy pathways that may be pursued to resolve the FTC's competitive concerns:

1. Full divestiture of Vectis Solutions LLC — the sale of 100% of Fund II's equity interest in Vectis to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition.

2. Partial divestiture of overlapping product lines or assets — a carve-out of specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap, while retaining the non-overlapping components of each business.

3. Behavioral or conduct remedies — structural separation measures such as firewall agreements, independent management requirements, pricing commitments, and FTC-monitored compliance programs, without any asset disposition.

Bottom-line assessment. Full divestiture of Vectis is the most likely remedy that the FTC would accept if the Commission determines that the Luminex-Vectis overlap is competitively problematic. This conclusion is driven by three factors: (i) the FTC's current strong preference for structural over behavioral remedies, particularly in technology markets; (ii) the availability of Vectis as a discrete, readily separable business that can be sold as a going concern; and (iii) the FTC's intensifying focus on common-control theories in the private equity context, which makes behavioral remedies (such as firewalls and independent management) particularly unlikely to satisfy the agency's concerns. Behavioral remedies alone are, in our assessment, very unlikely to be accepted by the current FTC. A partial divestiture is theoretically possible but carries significant execution risk and regulatory acceptance uncertainty, particularly given the integration of Luminex's procurement module into its broader Luminex One platform.

Recommendation. We recommend that the Ardent team pursue a dual-track strategy:

• Track 1 — Substantive Defense: Prepare a robust defense of the Transaction on the merits, arguing that the competitive overlap between Luminex and Vectis is narrow, that the two platforms serve distinct customer segments and offer differentiated products, that substantial competitive alternatives remain in the procurement-automation SaaS market, and that the Transaction will generate procompetitive efficiencies.

• Track 2 — Vectis Divestiture Package: In parallel, and on a confidential basis, begin preparing a credible Vectis divestiture package that can be deployed quickly if necessary to secure FTC clearance within the transaction timeline. This includes retaining an investment bank to market Vectis, identifying potential purchasers, preparing a data room, and engaging with the Ardent Fund II GP and LP advisory committee regarding the potential disposition.

The dual-track approach maximizes Ardent's optionality and minimizes the risk that the transaction timeline exceeds the Outside Date of September 10, 2025 (extendable to December 10, 2025 for regulatory delays). The Investment Committee briefing scheduled for April 18, 2025 is a critical milestone at which authorization should be sought for both tracks.

II. Background

A. The Transaction

Ardent Capital Partners III LP ("Fund III"), a Delaware limited partnership with its principal offices at 399 Park Avenue, 42nd Floor, New York, NY 10022, is acquiring Luminex Systems Holdings Inc. ("Luminex" or the "Target"), a Delaware corporation headquartered at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191, through a reverse triangular merger under the Delaware General Corporation Law. The acquisition is being effected through two special-purpose vehicles formed for the transaction:

• Ardent Apex Holdings Inc., a Delaware corporation incorporated on March 5, 2025, which serves as the direct parent of the merger subsidiary and will be the surviving entity's parent following the closing; and

• Ardent Apex Merger Sub Inc., a Delaware corporation incorporated on March 7, 2025, which will merge with and into Luminex, with Luminex surviving the merger as a wholly owned subsidiary of Ardent Apex Holdings Inc.

The Agreement and Plan of Merger (the "Merger Agreement") was executed on March 24, 2025. The transaction values Luminex at an aggregate equity value of $2,800,000,000. The per-share merger consideration is $20.00, payable in respect of approximately 140,000,000 fully diluted shares of Luminex common stock (inclusive of shares issuable upon exercise of outstanding options and settlement of restricted stock units).

The Target. Luminex is a Swiss-headquartered enterprise SaaS company. Its ultimate parent entity is Luminex Systems AG, a Swiss corporation (CHE-284.391.057) domiciled at Bahnhofstrasse 71, Zürich, Switzerland. Luminex provides cloud-based enterprise resource planning ("ERP"), procurement automation, and supply-chain analytics to large enterprise and mid-market customers globally through its integrated "Luminex One" platform. Luminex One is an end-to-end suite that combines procurement workflow automation, supplier management, spend analytics, contract lifecycle management, and supply-chain visibility tools into a unified, cloud-native architecture. The procurement-automation module is a core component of the Luminex One platform, but it is deeply integrated with the broader ERP and supply-chain capabilities and is not sold or deployed as a stand-alone product in most customer configurations.

Luminex's financial profile for fiscal year 2024 is as follows:

Luminex's revenue is distributed across the following key geographic markets: the DACH region (Germany, Austria, Switzerland), accounting for approximately 35% of total revenue; North America, accounting for approximately 40%; the United Kingdom and Nordics, accounting for approximately 15%; and the Asia-Pacific region, accounting for approximately 10%.

Luminex's U.S. operations are conducted through Luminex Systems Inc., a Delaware corporation that serves as the principal operating subsidiary for the North American market. In fiscal year 2024, Luminex Systems Inc. generated approximately $194,800,000 in revenue and employed approximately 1,650 personnel across its Reston, Virginia headquarters and satellite offices in Austin, Texas and San Francisco, California.

Selling shareholders. The principal selling shareholders in the Transaction are:

• Ridgeline Growth Equity Fund II LP — holding approximately 52% of the outstanding equity, with expected total consideration of approximately $1,456,000,000;

• Meridian Venture Partners IV LP — holding approximately 20% of the outstanding equity, with expected total consideration of approximately $560,000,000; and

• Management and employees — holding the remaining approximately 28% of the outstanding equity, with total consideration of approximately $784,000,000. Of this amount, approximately $405,020,000 will be rolled over into equity of Ardent Apex Holdings Inc. (the post-closing parent), and approximately $378,980,000 will be paid out in cash at closing.

The rollover by management reflects Ardent's standard practice of incentivizing management continuity in leveraged acquisitions and demonstrates the alignment of the existing management team with the go-forward investment thesis.

B. Vectis Solutions LLC — The Overlapping Portfolio Company

Vectis Solutions LLC ("Vectis") is a Delaware limited liability company (EIN: 82-4910337) headquartered at 4000 Shoreline Court, Suite 300, South San Francisco, California 94080. Vectis is led by its Chief Executive Officer, Michael Parekh, who has served in that capacity since 2020.

Vectis is a portfolio company of Ardent Capital Partners II LP ("Fund II"), the predecessor fund to Fund III within the Ardent Capital Partners fund family. Fund II acquired its controlling interest in Vectis in 2019 as part of a growth-equity investment. Fund II holds its interest in Vectis through intermediate holding entities, but the economic and governance control ultimately resides with the Fund II general partner, Ardent Capital GP II LLC, which is itself controlled by the same managing partners — Theodore "Ted" Hargrove and Victoria Langford — who control Ardent Capital GP III LLC, the general partner of Fund III.

Vectis generated total revenue of approximately $68,000,000 in fiscal year 2024, derived entirely from its procurement-automation SaaS platform. The Vectis platform is a cloud-native, point-solution offering focused specifically on procurement workflow automation, purchase-order management, invoice processing, and supplier onboarding. Unlike Luminex One, which provides an integrated ERP/procurement/supply-chain suite, Vectis is purpose-built as a standalone procurement-automation tool and is typically deployed alongside a customer's existing ERP system (e.g., Hollowell & Co., Ridgeline Industries, or Microsoft Dynamics).

Vectis maintains a German subsidiary, Vectis GmbH, which generated approximately €12,000,000 in revenue in fiscal year 2024. The German operations primarily serve mid-market customers in the manufacturing and industrial sectors across Germany and, to a lesser extent, Austria.

Vectis's primary customer base consists of mid-market and lower-enterprise-tier organizations, predominantly in the United States. Its product focus and customer profile overlap with the procurement-automation capabilities offered by Luminex's Luminex One platform, particularly in the North American and DACH markets. We estimate Vectis's share of the relevant procurement-automation SaaS market at approximately 7%.

C. Competitive Overlap and Market Concentration

The competitive overlap between Luminex and Vectis centers on the procurement-automation SaaS segment. Although Luminex offers its procurement module as part of a broader suite (Luminex One) and Vectis offers its procurement solution as a standalone product, the FTC is likely to define the relevant product market broadly enough to encompass both approaches, as they are functional substitutes from the perspective of enterprise and mid-market customers evaluating procurement-automation software.

Relevant product market. We expect the FTC to define the relevant product market as "procurement-automation SaaS platforms for enterprise and mid-market customers." This definition would encompass cloud-based software platforms that automate procurement workflows — including requisition-to-purchase-order processing, invoice automation, supplier management, spend analytics, and contract management — sold on a subscription (SaaS) basis to enterprise and mid-market organizations. The FTC may further refine this market definition based on evidence regarding customer substitution patterns, but even under a broader or narrower definition, the Luminex-Vectis overlap is likely to be captured.

Market shares and concentration. Based on our preliminary analysis of publicly available data, analyst reports, and internal information provided by both Luminex and Vectis, we estimate the following market shares in the procurement-automation SaaS market:

Following the Transaction, the combined Luminex-Vectis entity (under common Ardent control) would hold an estimated market share of approximately 25%, making the combined entity the second-largest player in the market behind Pemberton & Co..

Common-control analysis. It is important to note that Fund III (through Ardent Apex Holdings Inc.) is acquiring Luminex, while Fund II (a separate fund vehicle) holds Vectis. The FTC will nonetheless treat the post-closing Ardent fund family as a single economic entity for purposes of competitive analysis. This treatment is well-supported by the facts: Ardent Capital GP III LLC (the general partner of Fund III) and Ardent Capital GP II LLC (the general partner of Fund II) are controlled by the same managing partners — Ted Hargrove and Victoria Langford. The Investment Committees of both funds share substantially overlapping membership. Accordingly, the FTC will aggregate the Luminex and Vectis market shares and analyze the competitive effects of the Transaction as though a single firm were acquiring both businesses.

HHI analysis. The Herfindahl-Hirschman Index ("HHI") is the standard measure of market concentration used by the FTC and DOJ. Based on the estimated market shares set forth above, we calculate the following HHI values:

• Pre-merger HHI: Approximately 1,280 (calculated as: 22² + 18² + 12² + 11² + 9² + 8² + 7² + the sum of squared shares for the "other" category, estimated as several small players). This places the market in the "moderately concentrated" range under the 2023 Merger Guidelines.

• Post-merger HHI increase (ΔHHI): Approximately 252 (calculated as 2 × 18 × 7 = 252, reflecting the combination of Luminex's 18% share with Vectis's 7% share).

• Post-merger HHI: Approximately 1,532.

Under the 2023 FTC/DOJ Merger Guidelines, a transaction is presumptively likely to enhance market power where (i) the post-merger HHI exceeds 1,800 and (ii) the change in HHI exceeds 100. Here, the post-merger HHI of approximately 1,532 falls below the 1,800 threshold, but the ΔHHI of 252 substantially exceeds the 100-point threshold. The 2023 Merger Guidelines also identify transactions as concerning where the combined firm's market share exceeds 30% or where the ΔHHI exceeds 100 in a concentrated market. While the combined share of ~25% does not trigger the 30% structural presumption, the significant ΔHHI of 252 is likely to attract the FTC's attention, particularly given the FTC's current approach of looking holistically at market dynamics rather than relying exclusively on bright-line HHI thresholds.

In sum, the Transaction falls within the zone of close FTC scrutiny — not an automatic challenge under the structural presumption, but sufficiently concentrated to warrant a thorough investigation, particularly given the FTC's heightened interest in private equity common-control scenarios.

D. Regulatory Posture and Timeline

The following summarizes the current regulatory posture and critical timeline milestones:

HSR filing and FTC assignment. The HSR pre-merger notification was filed on March 28, 2025 (Transaction No. HSR-20250328-4192). The filing fee of $2,390,000 was paid by Ardent Apex Holdings Inc. as the acquiring person. On April 2, 2025, the filing was cleared to the FTC by the DOJ pursuant to the interagency clearance process. The initial 30-day waiting period under the HSR Act expires on April 27, 2025.

Anticipated Second Request. Based on the competitive overlap described in this memorandum, as well as preliminary staff inquiries that the FTC has directed to both parties since the filing, we anticipate that the FTC will issue a Second Request on or about April 25, 2025, prior to the expiration of the initial waiting period. Issuance of a Second Request would extend the HSR waiting period until 30 days after both parties have substantially complied with the request. In practice, Second Request compliance typically takes 2–4 months, and the post-compliance waiting period may be extended by agreement with FTC staff through a timing agreement.

Outside Date and extensions. The Merger Agreement establishes an Outside Date of September 10, 2025 — approximately six months from the date of signing. If, as of the Outside Date, the sole unsatisfied closing condition is the receipt of regulatory approval (including expiration or early termination of the HSR waiting period and any required foreign competition clearances), either party may extend the Outside Date by up to three months, to December 10, 2025. This extension mechanism provides a total maximum period of approximately nine months from signing for regulatory clearance.

Reverse termination fee. If Buyer fails to close the Transaction due to a financing failure or willful breach of the Merger Agreement, Buyer is obligated to pay a reverse termination fee ("RTF") of $140,000,000, representing 5.0% of the aggregate deal value. The RTF is the Sellers' sole and exclusive remedy in such a scenario. Importantly, however, the mere failure to obtain regulatory approval does not, by itself, trigger the RTF unless the failure is attributable to Buyer's willful breach of its regulatory efforts covenant.

Regulatory efforts covenant. The Merger Agreement imposes a "reasonable best efforts" obligation on Buyer to obtain all required regulatory approvals, including FTC clearance. This covenant requires Buyer to propose, negotiate, and agree to remedies reasonably necessary to obtain clearance, provided that such remedies do not constitute a "Burdensome Condition." The definition of "Burdensome Condition" in the Merger Agreement is a critical provision that we analyze in detail in Section V below. Notably, the Merger Agreement does not contain a "hell or high water" covenant — Buyer is not obligated to accept any and all remedies demanded by the FTC regardless of their impact on the transaction or Ardent's broader portfolio.

Additional regulatory filings. In addition to the HSR filing, the Transaction requires pre-merger notifications or filings in several additional jurisdictions, including Switzerland (Swiss FINMA/SECO, File No. 32-0973, filed April 7, 2025), Germany (Bundeskartellamt, File No. B6-34/25, filed April 9, 2025), and the EU (Foreign Subsidies Regulation filing, Case No. FSR.M.2025-0412, filed April 11, 2025). A voluntary CFIUS filing was submitted on April 4, 2025 (Tracking No. CFIUS-2025-0087). The Vectis competitive overlap may implicate the German and Swiss filings in addition to the HSR filing, which is discussed further in Section VII below.

III. FTC Analytical Framework

A. Substantive Standard

The FTC's authority to challenge the Transaction derives from Section 7 of the Clayton Act (15 U.S.C. § 18), which prohibits acquisitions where "the effect of such acquisition may be substantially to lessen competition, or to tend to create a monopoly" in any relevant market. Section 7 is an incipiency statute — it is designed to arrest anticompetitive trends in their early stages, before actual competitive harm materializes. The FTC bears the initial burden of establishing a prima facie case that the Transaction is likely to substantially lessen competition, after which the burden shifts to the merging parties to rebut the presumption with evidence of efficiencies, ease of entry, or other procompetitive justifications.

The 2023 FTC/DOJ Merger Guidelines (the "Merger Guidelines"), issued on December 18, 2023, set forth the analytical framework the agencies apply in evaluating mergers. The Merger Guidelines identify several "guidelines" (previously referred to as "presumptions") that inform the agencies' enforcement decisions. The most relevant guidelines for this Transaction are:

1. Guideline 1 — Market Concentration. Mergers should not significantly increase concentration in highly concentrated markets. A market is "highly concentrated" where the post-merger HHI exceeds 1,800. A merger "significantly increases concentration" where the change in HHI exceeds 100. As noted above, the post-merger HHI in the procurement-automation SaaS market is estimated at approximately 1,532, which falls below the 1,800 threshold. However, the ΔHHI of approximately 252 substantially exceeds the 100-point change threshold. While this means the Transaction may not trigger the formal structural presumption, the substantial increase in concentration will invite close FTC scrutiny.

2. Guideline 2 — Head-to-Head Competition. Mergers should not eliminate substantial competition between firms. This guideline focuses on direct competitive rivalry between the merging parties. The FTC will examine whether Luminex and Vectis compete head-to-head for the same procurement-automation SaaS customers and whether the elimination of that competition would harm customers. Evidence of direct competition — including win/loss data, customer switching patterns, and internal strategy documents referencing each firm as a competitor — will be central to this analysis.

3. Guideline 7 — Serial Acquisitions and Industry Roll-Ups. The 2023 Merger Guidelines introduced a new guideline specifically addressing patterns of serial acquisitions. The FTC will evaluate whether the Transaction, viewed in the context of Ardent's existing ownership of Vectis, is part of a pattern of acquisitions that individually or collectively may substantially lessen competition. This guideline is particularly relevant here because the Transaction involves a private equity sponsor acquiring a second significant player in the same market where it already holds a portfolio company.

In light of these guidelines, the FTC is likely to focus its investigation on the following evidentiary areas: (i) direct head-to-head competition between Luminex and Vectis for the same enterprise procurement-SaaS customers, including analysis of competitive bidding situations where both firms participated; (ii) win/loss data maintained by both companies, showing instances where customers chose Luminex over Vectis or vice versa; (iii) customer testimony regarding the competitive significance of Vectis as an alternative to Luminex and the potential impact of common ownership; and (iv) internal strategy documents from both Luminex and Vectis referencing each other as competitors, including market analyses, competitive positioning presentations, and pricing strategy documents.

B. Cross-Ownership / Common-Control Theory

A critical dimension of the FTC's analysis will be its increasingly aggressive focus on private equity cross-ownership and common-control in technology and software markets. The FTC has signaled — through public statements by the Chair and Commissioners, enforcement actions, and revisions to the HSR notification rules — that it views private equity roll-up strategies as a priority enforcement area.

The common-control theory applicable here is straightforward: Although Fund III (which is acquiring Luminex) and Fund II (which holds Vectis) are technically separate fund vehicles with distinct limited partnership agreements, separate investor bases, and separate capital accounts, the FTC will focus on the fact that both funds are ultimately controlled by the same general partner entities and the same managing partners. Specifically:

• Ardent Capital GP III LLC is the general partner of Fund III and controls the investment and governance decisions of the fund. Its managing members are Theodore "Ted" Hargrove and Victoria Langford.

• Ardent Capital GP II LLC is the general partner of Fund II and exercises the same control over Fund II's investment and governance decisions. Its managing members are likewise Ted Hargrove and Victoria Langford.

• The Investment Committee of Fund III consists of Ted Hargrove, Victoria Langford, Marcus Ellison, Priya Chandrasekaran, and David Ng. Based on available information, the Investment Committee of Fund II has the same or substantially overlapping membership.

Under these circumstances, the FTC will argue that post-closing, the same group of individuals — acting through Ardent's general partner and investment committee structures — would have the ability and incentive to coordinate the competitive strategies of both Luminex and Vectis, effectively eliminating the competitive tension between the two platforms. This is true even if Luminex and Vectis are maintained as operationally independent companies with separate management teams, because the ultimate investment and strategic decisions (including pricing strategy, product development priorities, customer targeting, and capital allocation) would be made or ratified by the same decision-makers.

The FTC's position on this point is supported by the economic literature on common ownership and by the Commission's own enforcement precedents. In several recent matters involving private equity acquisitions in healthcare, veterinary services, and enterprise software, the FTC has expressly rejected arguments that separate fund structures or separate management teams are sufficient to eliminate competitive concerns where the sponsor exercises common control over portfolio companies in the same market.

C. Efficiencies Defense

The merging parties may advance several procompetitive arguments in defense of the Transaction:

1. Distinct customer segments. Luminex and Vectis serve largely different customer populations. Luminex One is primarily marketed to large enterprise customers, particularly multinational corporations with complex, cross-border procurement and supply-chain operations. Its strongest market presence is in the DACH region and among Fortune 500 companies. Vectis, by contrast, is a mid-market-focused solution predominantly serving U.S.-based companies with annual revenues of $100 million to $2 billion. The degree of customer overlap may be limited, and the FTC's concern about elimination of head-to-head competition may be overstated if the two products compete for different customer segments.

2. Product differentiation. Luminex One is a full-suite ERP/procurement/supply-chain platform, while Vectis is a point solution focused exclusively on procurement automation. From a product-architecture standpoint, these are fundamentally different offerings. Customers selecting Luminex One are typically seeking a comprehensive, integrated enterprise platform, while customers selecting Vectis are typically seeking a best-of-breed procurement tool to complement an existing ERP system. The competitive dynamics between these two product categories are different from competition between two similar point solutions or two similar suite products.

3. Acquisition-specific efficiencies. Ardent's acquisition of Luminex is expected to generate acquisition-specific efficiencies through the combination of Luminex's platform capabilities with Ardent's operational expertise in scaling enterprise SaaS businesses. These efficiencies — including investments in product development, expansion into new geographic markets, and operational improvements — are not achievable absent the Transaction and would benefit customers through improved product quality and accelerated innovation.

4. Substantial remaining competition. Even at a combined market share of approximately 25%, the post-merger market would remain competitive, with at least five other significant players (Westmark Partners LLC, Meridian Corporation, Ostrander Industries, Halcyon Holdings, and Cobalt Ridge Holdings) collectively holding approximately 62% of the market. No single firm would dominate the market, and customers would retain meaningful competitive alternatives.

Challenges with the efficiencies defense. Notwithstanding the foregoing arguments, we must candidly assess the limitations of the efficiencies defense in the current enforcement environment. The FTC has been skeptical of claimed efficiencies in recent enforcement actions, consistently noting that efficiencies are difficult to verify, often overstated by merging parties, and frequently not merger-specific. The burden of proof rests squarely on the parties to demonstrate that claimed efficiencies are (i) merger-specific (not achievable through means other than the Transaction), (ii) verifiable (supported by credible evidence rather than speculative projections), and (iii) cognizable (not premised on anticompetitive reductions in output or quality). Additionally, it is inherently difficult to argue that a combined share of approximately 25% — placing the merged entity as the second-largest player in the market — is not competitively significant, particularly when the ΔHHI exceeds 250 points.

IV. Remedy Scenario Analysis

We have identified and evaluated three principal remedy scenarios that may be pursued to resolve the FTC's competitive concerns. Each scenario is analyzed below in terms of its description, feasibility, financial implications, advantages, and disadvantages.

A. Scenario 1: Full Divestiture of Vectis Solutions LLC

1. Description. Under this scenario, Ardent would sell 100% of its equity interest in Vectis Solutions LLC — held by Ardent Capital Partners II LP (Fund II) — to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition. The divestiture would encompass all of the assets of the Vectis business as a going concern, including:

• The Vectis procurement-automation SaaS platform, including all associated source code, object code, databases, algorithms, machine-learning models, and related technical documentation;

• All customer contracts, including subscription agreements, master services agreements, and statements of work;

• All employees, including the executive management team led by CEO Michael Parekh, as well as engineering, sales, marketing, customer success, and general and administrative personnel;

• Vectis GmbH, the German subsidiary, together with all of its assets, employees, and customer relationships;

• All intellectual property, including patents, patent applications, trademarks, trade secrets, copyrights, and domain names;

• All goodwill associated with the Vectis business; and

• All other tangible and intangible assets necessary for the operation of Vectis as a viable, independent, competitive business.

Michael Parekh and the Vectis management team would transfer to the purchaser as part of the going-concern sale, or alternatively would be subject to transition services arrangements to ensure business continuity during the ownership transition. In a typical FTC consent decree context, the Commission strongly prefers that key management personnel transfer with the divested business to preserve competitive viability.

2. Estimated Valuation and Financial Impact

The financial implications of a full Vectis divestiture are summarized as follows:

Vectis valuation. Vectis generated total revenue of $68,000,000 in fiscal year 2024. Applying comparable enterprise-value-to-revenue multiples for procurement-SaaS companies, which generally range from approximately 4.0x to 6.0x revenue based on recent transaction precedents and public-company trading comparables, the indicative enterprise value range for Vectis is:

The applicable multiple within this range will depend on Vectis's growth rate, customer retention metrics (net revenue retention, gross churn), profitability profile, competitive positioning, and the specific circumstances of the sale process (including the compressed timeline and regulatory-compulsion context, which may exert downward pressure on the achievable valuation).

Impact on Ardent Fund II returns. A full divestiture of Vectis would result in the loss of future upside potential on the Vectis investment for Fund II's limited partners. This loss would be partially offset by the sale proceeds received, which would be distributed to Fund II LPs in accordance with the Fund II limited partnership agreement. The tax implications of the disposition — including the potential for capital gains treatment, the impact on the fund's carried interest waterfall, and any state and local tax considerations — should be analyzed by Sylvia Hartwell and Pendleton & Associates LLP (contact: Richard Chow).

No impact on Luminex acquisition. Because Vectis is held by Fund II (not Fund III), the divestiture of Vectis has no direct financial impact on the Luminex acquisition's sources and uses. The $2,800,000,000 aggregate deal value for Luminex remains unchanged, and the financing commitments for the Luminex transaction are unaffected. However, Ardent's Fund II LPs and the GP's fiduciary obligations to those LPs are directly implicated, as discussed further below.

3. Process Considerations

FTC consent decree requirements. In a typical FTC consent decree involving a divestiture remedy, the Commission imposes detailed requirements designed to ensure that the divested business remains a viable and effective competitor in the relevant market. These requirements typically include:

• The purchaser must have the financial capability to operate and invest in the divested business on an ongoing basis;

• The purchaser must have industry expertise or a credible plan for acquiring the necessary expertise to compete effectively in the procurement-SaaS market;

• The purchaser must be independent of the divesting party — i.e., the purchaser cannot be an Ardent affiliate, co-investor, or entity that would maintain any economic or governance connection to Ardent;

• The divestiture must include all assets necessary for the purchaser to operate the business as a going concern, without reliance on transitional support from the divesting party except for a limited, time-bounded transition services period; and

• The FTC may require the appointment of an interim monitor or divestiture trustee to oversee the sale process and ensure compliance with the consent decree terms.

Upfront buyer requirement. Given the current FTC's preference for certainty of execution, the Commission may require an "upfront buyer" — meaning that the identity of the purchaser must be identified and approved by the FTC before the consent decree is finalized. This approach provides the FTC with assurance that the divestiture will be completed to a qualified buyer, rather than leaving the outcome of the sale process uncertain. If an upfront buyer is required, Ardent would need to conduct a pre-signing marketing process for Vectis in parallel with the FTC investigation, adding complexity to the overall timeline.

Timeline considerations. If the FTC issues a Second Request on or about April 25, 2025, the typical investigation period — including compliance with the Second Request, FTC staff review of the produced documents and data, depositions, and staff recommendation — may take 6 to 12 months. Consent decree negotiations, if the parties and the FTC reach agreement on a divestiture remedy, often occur in parallel with the later stages of the investigation and can add an additional 2 to 3 months. Based on this timeline, it is feasible that the Luminex closing could occur by approximately August to October 2025, assuming the FTC investigation is managed efficiently and consent decree negotiations proceed in good faith.

However, if the Vectis divestiture process is complex or if identifying an FTC-approved buyer takes longer than expected, the timeline could extend beyond the September 10, 2025 Outside Date. In that event, the parties would need to invoke the three-month regulatory extension provision in the Merger Agreement, extending the Outside Date to December 10, 2025.

Conflict of interest considerations. Calderwood & Harkness has represented Vectis Solutions LLC in other matters, and a conflict waiver letter has been executed to address the potential divergence of interests between Vectis and Fund III in a divestiture scenario. Notwithstanding the waiver, if a Vectis divestiture becomes necessary, Calderwood & Harkness should not serve as divestiture counsel for Vectis (i.e., representing Vectis as the seller in the sale process). Vectis and/or Fund II should retain independent outside counsel for the divestiture transaction to avoid the creation of additional conflicts of interest. This issue is discussed further in Section VI below.

4. Advantages.

• Cleanest remedy. A full Vectis divestiture eliminates the competitive overlap entirely. There is no residual issue of common ownership in the procurement-automation SaaS market, and no ongoing compliance obligations or monitoring requirements.

• Most likely to satisfy FTC quickly. Given the FTC's strong preference for structural remedies and its skepticism of behavioral alternatives, a full Vectis divestiture is the remedy most likely to secure prompt FTC acceptance and avoid protracted negotiation or litigation.

• Preserves full strategic value of Luminex acquisition. The $2.8 billion Luminex acquisition — the centerpiece of Ardent Fund III's investment strategy — proceeds unimpaired. No carve-outs, restrictions, or modifications to the Luminex business are required.

• Avoids risk of protracted FTC litigation. If the FTC determines that the overlap is competitively significant and the parties are unable to agree on a remedy, the Commission may seek a preliminary injunction in federal court to block the Transaction. FTC litigation is costly, time-consuming, and uncertain in outcome. A Vectis divestiture moots the competitive concern and eliminates the litigation risk.

5. Disadvantages.

• Loss of a valuable portfolio asset for Fund II. Vectis is a high-growth procurement-SaaS business with substantial value. A forced divestiture deprives Fund II's limited partners of the future upside potential of the investment, including the possibility that Vectis could be grown and eventually sold or taken public at a higher valuation.

• Potential fire-sale discount. If the Vectis sale is conducted under regulatory compulsion with a compressed timeline, potential buyers may exploit the circumstances to negotiate a lower purchase price. The FTC's requirement that the buyer be pre-approved and the consent decree's deadline for completion of the divestiture may further limit Ardent's negotiating leverage.

• Management resistance. Michael Parekh and the Vectis management team may resist the divestiture or seek enhanced financial terms (e.g., accelerated vesting of equity incentives, retention bonuses, or enhanced severance protections) as a condition of their cooperation. Management resistance could slow the process and complicate the sale.

• Fund II LPA considerations. Depending on the terms of the Fund II limited partnership agreement, a disposition of a significant portfolio company may require approval from the LP advisory committee or may trigger other governance requirements. Ardent Capital GP II LLC, as the general partner of Fund II, owes fiduciary duties to the Fund II limited partners, and a decision to divest Vectis in order to facilitate a Fund III transaction raises inherent conflicts of interest that must be carefully managed. We recommend consulting with Ardent's GP counsel on these issues.

B. Scenario 2: Partial Divestiture — Carve-Out of Overlapping Product Lines or Customer Segments

1. Description. Under this scenario, rather than divesting Vectis in its entirety, Ardent would divest only the specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap with the other company's offerings. This approach seeks to preserve maximum value across both portfolio companies while addressing the FTC's competitive concerns in a targeted manner. We have identified two principal sub-options:

• Option 2A — Carve out Luminex's procurement module. Luminex's stand-alone procurement-automation module would be separated from the Luminex One platform and divested to a third-party purchaser. The purchaser would receive the procurement module's code base, related intellectual property, and potentially a subset of Luminex's procurement-focused customer contracts. The remaining components of Luminex One (ERP, supply-chain analytics, contract lifecycle management) would be retained by Ardent.

• Option 2B — Carve out a subset of Vectis's enterprise customers. A subset of Vectis's customer base — specifically, the enterprise-tier customers whose procurement needs most directly overlap with Luminex's offerings — would be separated from the Vectis business and divested to a third party, together with the associated customer contracts, account management personnel, and a license to the Vectis platform. Vectis would retain its mid-market customer base and continue to operate as an Ardent Fund II portfolio company.

2. Feasibility Assessment

Option 2A — Luminex procurement module carve-out. This option presents formidable technical and commercial challenges. The procurement-automation functionality within Luminex One is deeply integrated into the platform's architecture. The procurement module shares a common data model, user interface framework, authentication and security infrastructure, and application programming interfaces (APIs) with the other components of Luminex One. Separating the procurement module into a stand-alone product would require significant re-engineering effort, potentially taking 12 to 18 months or longer. Moreover, the carved-out procurement module would likely not be a commercially viable stand-alone business, as it was designed to function as part of an integrated suite and lacks the independent go-to-market infrastructure (sales team, marketing, customer support) to compete effectively on its own.

From a regulatory perspective, the FTC is unlikely to accept a partial divestiture that results in a non-viable stand-alone business. The Commission's consent decree standards require that the divested assets be sufficient to enable the purchaser to compete effectively in the relevant market. A carved-out Luminex procurement module that cannot function independently, or that requires extensive re-engineering before it can be deployed by customers, would not satisfy this standard.

We do not recommend Option 2A.

Option 2B — Vectis enterprise customer carve-out. This option is more feasible than Option 2A from a technical standpoint, because Vectis is a point solution with a relatively modular architecture, and its customer contracts are structured as individual subscription agreements that can, in principle, be assigned to a third-party purchaser. However, several significant challenges remain:

• Customer segmentation. The FTC would need to be satisfied that the divested customer segment is the segment that creates the competitive overlap with Luminex. If Vectis's enterprise customers are divested but the remaining mid-market customers continue to overlap with Luminex's customer base (which also includes some mid-market accounts), the FTC may view the partial divestiture as insufficient.

• Platform viability. The purchaser of Vectis's enterprise customers would need access to the Vectis platform to serve those customers. This would require either (a) a transfer of the Vectis platform code base and IP to the purchaser (which essentially becomes a full divestiture minus the mid-market customer base) or (b) a long-term license of the Vectis platform to the purchaser, which introduces ongoing dependency on Ardent/Vectis and is unlikely to satisfy the FTC's stand-alone viability requirements.

• Employee transfers. The engineering team that maintains and develops the Vectis platform would likely need to transfer in whole or in part with the divested business, further eroding the value of the retained Vectis mid-market business.

We view Option 2B as theoretically possible but practically challenging and uncertain in terms of FTC acceptance. Significant additional technical due diligence would be required to determine the separability of the code base, data infrastructure, and customer deployments before this option could be developed into a credible remedy proposal.

3. Advantages.

• Preserves partial value of both portfolio companies. If executed successfully, a partial divestiture would allow Ardent to retain portions of both the Luminex and Vectis businesses, preserving value for both Fund III and Fund II investors.

• Targeted remedy. A partial divestiture addresses only the specific area of overlap, rather than requiring a wholesale disposition of an entire portfolio company. This may be viewed as a more proportionate remedy relative to the competitive concern.

4. Disadvantages.

• Execution complexity and cost. Carving out product lines or customer segments from an integrated software business requires extensive technical work, including data migration, code separation, transition services agreements, IP licensing arrangements, and employee transfers. These processes are time-consuming, expensive, and prone to error.

• FTC skepticism. The FTC has historically viewed partial divestitures in technology markets with considerable skepticism, preferring "clean sweep" structural remedies that eliminate any ongoing relationship between the divesting party and the divested business. FTC staff may conclude that a partial divestiture is designed to preserve the parties' commercial interests at the expense of competitive effectiveness.

• Risk of creating a non-viable asset. If the carved-out business cannot function effectively as a stand-alone entity, it may fail in the market, which would not only harm customers and competition but also invite the FTC to revisit the consent decree and potentially seek additional relief. The risk of "remedy failure" is a significant concern for both the parties and the FTC.

• Longer negotiation timeline. Negotiating a partial divestiture with FTC staff is inherently more complex than negotiating a full divestiture, because the parties and the FTC must agree on the precise scope of the assets to be divested, the adequacy of transition services, the viability of the stand-alone business, and the qualifications of the purchaser to operate a more narrowly defined business. This extended negotiation timeline increases the risk of exceeding the Outside Date.

• Residual overlap risk. Depending on how the partial divestiture is structured, the FTC may conclude that the combined share in the remaining product segments or customer categories still exceeds the Commission's competitive-concern thresholds. This is particularly true if the FTC defines the relevant market broadly enough to encompass both the divested and retained segments.

C. Scenario 3: Behavioral / Conduct Remedies

1. Description. Under this scenario, Ardent would not divest any assets. Instead, it would agree to implement behavioral or conduct-based measures designed to maintain competitive independence between Luminex and Vectis while both remain under common Ardent ownership. The specific behavioral remedies that could be proposed include:

• Firewall agreements. Ardent would establish formal information barriers between the Luminex and Vectis management and commercial teams. The firewalls would restrict the sharing of competitively sensitive information — including pricing data, customer lists, bid strategies, product roadmaps, and competitive strategy — between the two companies. Ardent investment professionals who interact with both portfolio companies would be subject to protocols governing the handling of competitively sensitive information.

• Independent management. Vectis would continue to be managed by Michael Parekh as CEO, with independent authority over commercial strategy, pricing, product development, and customer engagement. Ardent investment professionals would be restricted from simultaneously serving on the boards of directors (or equivalent governing bodies) of both Luminex and Vectis. Each company would maintain a separate board with a majority of independent directors.

• Pricing commitments. Ardent would commit to maintaining independent pricing for the Luminex One procurement modules and the Vectis platform for a specified period (e.g., five to ten years). Neither company would be permitted to coordinate pricing with the other, and pricing decisions would be made independently by each company's management team.

• Compliance monitoring. Ardent would agree to the appointment of an FTC-designated compliance monitor — an independent third party — to oversee compliance with the behavioral conditions for a defined period (e.g., five to ten years). The monitor would have access to relevant records, personnel, and communications of both Luminex and Vectis, and would report periodically to the FTC on compliance status.

2. FTC Receptiveness

Our assessment of the current FTC's receptiveness to behavioral remedies in this case is highly unfavorable. Several factors support this conclusion:

• Current FTC leadership strongly disfavors behavioral remedies. The FTC Chair and a majority of the Commissioners have publicly stated — in speeches, policy statements, and written concurrences — that structural remedies (divestitures) are the preferred means of addressing competitive harm in merger cases, and that behavioral remedies are disfavored because they are difficult to design, difficult to monitor, easy to circumvent, and not self-enforcing.

• Recent enforcement precedents. In virtually all recent FTC consent decrees in technology and software markets, the Commission has required structural remedies. Behavioral-only consent decrees have been exceedingly rare, and where they have been approved, they typically involve situations where a structural remedy was not feasible or where the competitive overlap was de minimis.

• Common-control theory. The FTC's core concern in this case is that common Ardent ownership of Luminex and Vectis would eliminate the competitive incentive between the two companies. Behavioral remedies such as firewalls and independent management do not address this fundamental concern. Even with robust firewalls in place, the FTC will argue that the same individuals (Ted Hargrove, Victoria Langford, and their Investment Committee colleagues) will ultimately make the strategic decisions for both companies, and that the economic incentive to coordinate rather than compete will inevitably prevail over paper-based compliance measures.

• Availability of a structural alternative. The FTC is particularly unlikely to accept behavioral remedies where a clean structural remedy is readily available. Vectis is a discrete, going-concern business that can be sold in its entirety to an independent purchaser. The FTC will view a behavioral-remedy proposal as an attempt to avoid the obvious structural solution and will likely reject it out of hand.

Assessment: We assign a very low probability — less than 10% — that the FTC would accept a behavioral-only remedy in this case.

3. Advantages.

• No asset disposition required. Ardent retains ownership of both Luminex and Vectis, preserving the investment thesis for both Fund III and Fund II.

• Preserves fund economics. Both Fund II (Vectis) and Fund III (Luminex) achieve their target returns without the dilution caused by a forced divestiture at a potentially suboptimal valuation.

4. Disadvantages.

• FTC highly unlikely to accept. As discussed above, the current enforcement environment makes FTC acceptance of behavioral-only remedies exceedingly improbable in this case.

• Ongoing compliance burdens. Even if behavioral remedies were accepted, they would impose significant ongoing compliance costs and operational burdens on Ardent, Luminex, and Vectis for the duration of the consent decree (potentially five to ten years or longer).

• Monitoring costs. The costs of the FTC-appointed compliance monitor — including the monitor's fees, expenses, and the internal resources required to support the monitor's oversight activities — would be borne by the parties.

• Does not address fundamental concern. Behavioral remedies do not address the FTC's core concern about common-control incentives. The Commission will view firewalls and independent management protocols as temporary and inherently unreliable safeguards that do not change the underlying economic incentives of common ownership.

• Strategic signaling risk. Offering behavioral-only remedies early in the FTC negotiation process could signal to FTC staff that the parties lack confidence in their substantive defense and are eager to reach a settlement at any cost. This could embolden FTC staff to push for broader structural relief — potentially extending beyond the Vectis overlap to other aspects of the Transaction. We strongly recommend that any behavioral-remedy proposal be offered only as a fallback or supplement to a structural remedy, and only in the context of a carefully negotiated consent decree.

V. Impact on Merger Agreement Provisions

A. Regulatory Efforts Covenant

The Merger Agreement imposes a "reasonable best efforts" obligation on Buyer (Ardent Apex Holdings Inc.) to obtain all required governmental and regulatory approvals, including FTC clearance under the HSR Act. This covenant is set forth in Section 6.04 of the Merger Agreement and requires Buyer to take commercially reasonable actions to obtain clearance, including:

• Filing all required notifications and applications with governmental authorities in a timely manner;

• Cooperating with FTC staff during the review process, including responding to informal inquiries, producing documents and data pursuant to any Second Request, and making witnesses available for depositions and interviews;

• Proposing, negotiating, and agreeing to remedies reasonably necessary to obtain FTC clearance, provided that such remedies do not constitute a "Burdensome Condition" (as defined in the Merger Agreement); and

• Not taking any action that would reasonably be expected to materially delay or impair the prospects of obtaining FTC clearance.

The "Burdensome Condition" definition is the critical limitation on Buyer's obligations. While we have not reproduced the full contractual text here (see Appendix B for relevant excerpts), the definition is generally understood to encompass any remedy, condition, or undertaking that would:

(a) Require the divestiture, license, or other disposition of assets, businesses, or product lines of Luminex or any of its subsidiaries generating aggregate annual revenues in excess of a specified dollar threshold;

(b) Impose restrictions on the post-closing operations or business conduct of Luminex or any of its subsidiaries that would materially impair the strategic rationale for the Transaction or materially diminish the expected financial returns; or

(c) Otherwise require Buyer or any of its affiliates to take actions that are materially disproportionate to the competitive concern being addressed.

Analysis — Would a full Vectis divestiture constitute a "Burdensome Condition"? In our assessment, the answer is likely no, for the following reasons:

First, the Burdensome Condition definition, as typically drafted in private equity acquisition agreements, is focused on divestitures or restrictions affecting the acquired business — i.e., Luminex and its subsidiaries. A divestiture of Vectis, which is a separate portfolio company held by a separate fund (Fund II), does not involve the disposition of any Luminex assets and does not impose any restriction on Luminex's post-closing operations. Accordingly, a Vectis divestiture likely falls outside the scope of the Burdensome Condition definition.

Second, the Burdensome Condition carve-out is designed to protect Buyer against being compelled to sacrifice the economic value of the acquisition itself — not to insulate Buyer from any regulatory burden that may affect its broader portfolio. The divestiture of a $272 million to $408 million Fund II asset to facilitate the closing of a $2.8 billion Fund III acquisition is not, on its face, disproportionate.

However, there is an important nuance: While a Vectis divestiture may not constitute a "Burdensome Condition" under the Merger Agreement, Ardent's willingness to divest a Fund II asset to close a Fund III deal raises separate fiduciary duty concerns. Ardent Capital GP II LLC owes fiduciary duties to the limited partners of Fund II, and a decision to divest Vectis — potentially at a discounted price and on a compressed timeline — in order to benefit a separate fund raises inherent conflicts of interest. These conflicts must be managed through appropriate governance processes, including LP advisory committee consultation and, potentially, independent counsel for the Fund II GP.

B. Outside Date and Extension

The Merger Agreement establishes an Outside Date of September 10, 2025, approximately six months from the date of signing (March 24, 2025). If, as of the Outside Date, the sole unsatisfied closing condition is the receipt of regulatory approval (including expiration or early termination of the HSR waiting period and any required foreign regulatory clearances), either

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP 7 Times Square New York, NY 10036
INTERNAL MEMORANDUM
Matter No.: 1001-00004
Date: April 14, 2025
To: James Prentice, Esq. (Responsible Partner, Mergers & Acquisitions) Sandra Tung, Esq. (Billing Partner, Mergers & Acquisitions)
From: Elaine Forsythe, Esq. (Specialist Partner, Antitrust & Competition) Ryan Kowalski, Esq. (Lead Associate, Mergers & Acquisitions) Megan Chu, Esq. (Working Associate, Mergers & Acquisitions)
Re: Remedies and Divestiture Analysis — Competitive Overlap Between Luminex Systems Holdings Inc. and Vectis Solutions LLC in Procurement-Automation SaaS
PRIVILEGE NOTICE: This memorandum is protected by the attorney-client privilege and the work-product doctrine. It has been prepared by attorneys at Calderwood & Harkness LLP in connection with the pending acquisition of Luminex Systems Holdings Inc. by Ardent Apex Holdings Inc. / Ardent Capital Partners III LP and reflects confidential legal analysis, mental impressions, conclusions, and strategic recommendations of counsel. This memorandum is not to be distributed, disclosed, or otherwise made available to any person or entity outside of Calderwood & Harkness LLP without the prior written approval of James Prentice or Elaine Forsythe. Any inadvertent disclosure does not constitute a waiver of any applicable privilege or protection.
Right-click to update Table of Contents
I. Executive Summary
This memorandum analyzes the potential remedies that the Federal Trade Commission ("FTC") may require to address the horizontal competitive overlap arising from Ardent Capital Partners III LP's ("Fund III") simultaneous ownership — through its sponsor group's affiliated funds — of Vectis Solutions LLC ("Vectis"), an existing portfolio company of Ardent Capital Partners II LP ("Fund II"), and Luminex Systems Holdings Inc. ("Luminex" or the "Target"), the target of the pending $2,800,000,000 reverse triangular merger (the "Transaction"). The overlap between these two businesses in the procurement-automation software-as-a-service ("SaaS") market is the central competitive concern and the focus of this analysis.
The core antitrust concern is straightforward: Following the closing of the Transaction, the Ardent fund family — through the common management and governance of Ardent Capital GP III LLC and Ardent Capital GP II LLC — would exercise control over two significant competitors in the procurement-automation SaaS market. Luminex holds an estimated market share of approximately 18%, and Vectis holds an estimated market share of approximately 7%, resulting in a combined post-acquisition market share of approximately 25%. While this combined share does not automatically trigger the structural presumption under the 2023 FTC/DOJ Merger Guidelines (which generally applies at a 30% threshold), it falls squarely within the zone of heightened FTC scrutiny, particularly in light of the current Commission's aggressive enforcement posture toward private equity roll-ups and serial acquisitions in technology markets.
Regulatory status. The parties filed their pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") on March 28, 2025 (Transaction No. HSR-20250328-4192). The filing was allocated to the FTC by the Department of Justice Antitrust Division on April 2, 2025, and the initial 30-day waiting period is set to expire on April 27, 2025. Based on preliminary staff inquiries received during the first two weeks following the filing, as well as the nature and magnitude of the competitive overlap, we anticipate that the FTC will issue a Request for Additional Information and Documentary Material (a "Second Request") on or about April 25, 2025. The issuance of a Second Request would extend the waiting period and trigger a substantially more intensive investigation.
Remedy pathways. This memorandum evaluates three principal remedy pathways that may be pursued to resolve the FTC's competitive concerns:
1.  Full divestiture of Vectis Solutions LLC — the sale of 100% of Fund II's equity interest in Vectis to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition.
2.  Partial divestiture of overlapping product lines or assets — a carve-out of specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap, while retaining the non-overlapping components of each business.
3.  Behavioral or conduct remedies — structural separation measures such as firewall agreements, independent management requirements, pricing commitments, and FTC-monitored compliance programs, without any asset disposition.
Bottom-line assessment. Full divestiture of Vectis is the most likely remedy that the FTC would accept if the Commission determines that the Luminex-Vectis overlap is competitively problematic. This conclusion is driven by three factors: (i) the FTC's current strong preference for structural over behavioral remedies, particularly in technology markets; (ii) the availability of Vectis as a discrete, readily separable business that can be sold as a going concern; and (iii) the FTC's intensifying focus on common-control theories in the private equity context, which makes behavioral remedies (such as firewalls and independent management) particularly unlikely to satisfy the agency's concerns. Behavioral remedies alone are, in our assessment, very unlikely to be accepted by the current FTC. A partial divestiture is theoretically possible but carries significant execution risk and regulatory acceptance uncertainty, particularly given the integration of Luminex's procurement module into its broader Luminex One platform.
Recommendation. We recommend that the Ardent team pursue a dual-track strategy:
•  Track 1 — Substantive Defense: Prepare a robust defense of the Transaction on the merits, arguing that the competitive overlap between Luminex and Vectis is narrow, that the two platforms serve distinct customer segments and offer differentiated products, that substantial competitive alternatives remain in the procurement-automation SaaS market, and that the Transaction will generate procompetitive efficiencies.
•  Track 2 — Vectis Divestiture Package: In parallel, and on a confidential basis, begin preparing a credible Vectis divestiture package that can be deployed quickly if necessary to secure FTC clearance within the transaction timeline. This includes retaining an investment bank to market Vectis, identifying potential purchasers, preparing a data room, and engaging with the Ardent Fund II GP and LP advisory committee regarding the potential disposition.
The dual-track approach maximizes Ardent's optionality and minimizes the risk that the transaction timeline exceeds the Outside Date of September 10, 2025 (extendable to December 10, 2025 for regulatory delays). The Investment Committee briefing scheduled for April 18, 2025 is a critical milestone at which authorization should be sought for both tracks.
II. Background
A. The Transaction
Ardent Capital Partners III LP ("Fund III"), a Delaware limited partnership with its principal offices at 399 Park Avenue, 42nd Floor, New York, NY 10022, is acquiring Luminex Systems Holdings Inc. ("Luminex" or the "Target"), a Delaware corporation headquartered at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191, through a reverse triangular merger under the Delaware General Corporation Law. The acquisition is being effected through two special-purpose vehicles formed for the transaction:
•  Ardent Apex Holdings Inc., a Delaware corporation incorporated on March 5, 2025, which serves as the direct parent of the merger subsidiary and will be the surviving entity's parent following the closing; and
•  Ardent Apex Merger Sub Inc., a Delaware corporation incorporated on March 7, 2025, which will merge with and into Luminex, with Luminex surviving the merger as a wholly owned subsidiary of Ardent Apex Holdings Inc.
The Agreement and Plan of Merger (the "Merger Agreement") was executed on March 24, 2025. The transaction values Luminex at an aggregate equity value of $2,800,000,000. The per-share merger consideration is $20.00, payable in respect of approximately 140,000,000 fully diluted shares of Luminex common stock (inclusive of shares issuable upon exercise of outstanding options and settlement of restricted stock units).
The Target. Luminex is a Swiss-headquartered enterprise SaaS company. Its ultimate parent entity is Luminex Systems AG, a Swiss corporation (CHE-284.391.057) domiciled at Bahnhofstrasse 71, Zürich, Switzerland. Luminex provides cloud-based enterprise resource planning ("ERP"), procurement automation, and supply-chain analytics to large enterprise and mid-market customers globally through its integrated "Luminex One" platform. Luminex One is an end-to-end suite that combines procurement workflow automation, supplier management, spend analytics, contract lifecycle management, and supply-chain visibility tools into a unified, cloud-native architecture. The procurement-automation module is a core component of the Luminex One platform, but it is deeply integrated with the broader ERP and supply-chain capabilities and is not sold or deployed as a stand-alone product in most customer configurations.
Luminex's financial profile for fiscal year 2024 is as follows:
Luminex's revenue is distributed across the following key geographic markets: the DACH region (Germany, Austria, Switzerland), accounting for approximately 35% of total revenue; North America, accounting for approximately 40%; the United Kingdom and Nordics, accounting for approximately 15%; and the Asia-Pacific region, accounting for approximately 10%.
Luminex's U.S. operations are conducted through Luminex Systems Inc., a Delaware corporation that serves as the principal operating subsidiary for the North American market. In fiscal year 2024, Luminex Systems Inc. generated approximately $194,800,000 in revenue and employed approximately 1,650 personnel across its Reston, Virginia headquarters and satellite offices in Austin, Texas and San Francisco, California.
Selling shareholders. The principal selling shareholders in the Transaction are:
•  Ridgeline Growth Equity Fund II LP — holding approximately 52% of the outstanding equity, with expected total consideration of approximately $1,456,000,000;
•  Meridian Venture Partners IV LP — holding approximately 20% of the outstanding equity, with expected total consideration of approximately $560,000,000; and
•  Management and employees — holding the remaining approximately 28% of the outstanding equity, with total consideration of approximately $784,000,000. Of this amount, approximately $405,020,000 will be rolled over into equity of Ardent Apex Holdings Inc. (the post-closing parent), and approximately $378,980,000 will be paid out in cash at closing.
The rollover by management reflects Ardent's standard practice of incentivizing management continuity in leveraged acquisitions and demonstrates the alignment of the existing management team with the go-forward investment thesis.
B. Vectis Solutions LLC — The Overlapping Portfolio Company
Vectis Solutions LLC ("Vectis") is a Delaware limited liability company (EIN: 82-4910337) headquartered at 4000 Shoreline Court, Suite 300, South San Francisco, California 94080. Vectis is led by its Chief Executive Officer, Michael Parekh, who has served in that capacity since 2020.
Vectis is a portfolio company of Ardent Capital Partners II LP ("Fund II"), the predecessor fund to Fund III within the Ardent Capital Partners fund family. Fund II acquired its controlling interest in Vectis in 2019 as part of a growth-equity investment. Fund II holds its interest in Vectis through intermediate holding entities, but the economic and governance control ultimately resides with the Fund II general partner, Ardent Capital GP II LLC, which is itself controlled by the same managing partners — Theodore "Ted" Hargrove and Victoria Langford — who control Ardent Capital GP III LLC, the general partner of Fund III.
Vectis generated total revenue of approximately $68,000,000 in fiscal year 2024, derived entirely from its procurement-automation SaaS platform. The Vectis platform is a cloud-native, point-solution offering focused specifically on procurement workflow automation, purchase-order management, invoice processing, and supplier onboarding. Unlike Luminex One, which provides an integrated ERP/procurement/supply-chain suite, Vectis is purpose-built as a standalone procurement-automation tool and is typically deployed alongside a customer's existing ERP system (e.g., Hollowell & Co., Ridgeline Industries, or Microsoft Dynamics).
Vectis maintains a German subsidiary, Vectis GmbH, which generated approximately €12,000,000 in revenue in fiscal year 2024. The German operations primarily serve mid-market customers in the manufacturing and industrial sectors across Germany and, to a lesser extent, Austria.
Vectis's primary customer base consists of mid-market and lower-enterprise-tier organizations, predominantly in the United States. Its product focus and customer profile overlap with the procurement-automation capabilities offered by Luminex's Luminex One platform, particularly in the North American and DACH markets. We estimate Vectis's share of the relevant procurement-automation SaaS market at approximately 7%.
C. Competitive Overlap and Market Concentration
The competitive overlap between Luminex and Vectis centers on the procurement-automation SaaS segment. Although Luminex offers its procurement module as part of a broader suite (Luminex One) and Vectis offers its procurement solution as a standalone product, the FTC is likely to define the relevant product market broadly enough to encompass both approaches, as they are functional substitutes from the perspective of enterprise and mid-market customers evaluating procurement-automation software.
Relevant product market. We expect the FTC to define the relevant product market as "procurement-automation SaaS platforms for enterprise and mid-market customers." This definition would encompass cloud-based software platforms that automate procurement workflows — including requisition-to-purchase-order processing, invoice automation, supplier management, spend analytics, and contract management — sold on a subscription (SaaS) basis to enterprise and mid-market organizations. The FTC may further refine this market definition based on evidence regarding customer substitution patterns, but even under a broader or narrower definition, the Luminex-Vectis overlap is likely to be captured.
Market shares and concentration. Based on our preliminary analysis of publicly available data, analyst reports, and internal information provided by both Luminex and Vectis, we estimate the following market shares in the procurement-automation SaaS market:
Following the Transaction, the combined Luminex-Vectis entity (under common Ardent control) would hold an estimated market share of approximately 25%, making the combined entity the second-largest player in the market behind Pemberton & Co..
Common-control analysis. It is important to note that Fund III (through Ardent Apex Holdings Inc.) is acquiring Luminex, while Fund II (a separate fund vehicle) holds Vectis. The FTC will nonetheless treat the post-closing Ardent fund family as a single economic entity for purposes of competitive analysis. This treatment is well-supported by the facts: Ardent Capital GP III LLC (the general partner of Fund III) and Ardent Capital GP II LLC (the general partner of Fund II) are controlled by the same managing partners — Ted Hargrove and Victoria Langford. The Investment Committees of both funds share substantially overlapping membership. Accordingly, the FTC will aggregate the Luminex and Vectis market shares and analyze the competitive effects of the Transaction as though a single firm were acquiring both businesses.
HHI analysis. The Herfindahl-Hirschman Index ("HHI") is the standard measure of market concentration used by the FTC and DOJ. Based on the estimated market shares set forth above, we calculate the following HHI values:
•  Pre-merger HHI: Approximately 1,280 (calculated as: 22² + 18² + 12² + 11² + 9² + 8² + 7² + the sum of squared shares for the "other" category, estimated as several small players). This places the market in the "moderately concentrated" range under the 2023 Merger Guidelines.
•  Post-merger HHI increase (ΔHHI): Approximately 252 (calculated as 2 × 18 × 7 = 252, reflecting the combination of Luminex's 18% share with Vectis's 7% share).
•  Post-merger HHI: Approximately 1,532.
Under the 2023 FTC/DOJ Merger Guidelines, a transaction is presumptively likely to enhance market power where (i) the post-merger HHI exceeds 1,800 and (ii) the change in HHI exceeds 100. Here, the post-merger HHI of approximately 1,532 falls below the 1,800 threshold, but the ΔHHI of 252 substantially exceeds the 100-point threshold. The 2023 Merger Guidelines also identify transactions as concerning where the combined firm's market share exceeds 30% or where the ΔHHI exceeds 100 in a concentrated market. While the combined share of ~25% does not trigger the 30% structural presumption, the significant ΔHHI of 252 is likely to attract the FTC's attention, particularly given the FTC's current approach of looking holistically at market dynamics rather than relying exclusively on bright-line HHI thresholds.
In sum, the Transaction falls within the zone of close FTC scrutiny — not an automatic challenge under the structural presumption, but sufficiently concentrated to warrant a thorough investigation, particularly given the FTC's heightened interest in private equity common-control scenarios.
D. Regulatory Posture and Timeline
The following summarizes the current regulatory posture and critical timeline milestones:
HSR filing and FTC assignment. The HSR pre-merger notification was filed on March 28, 2025 (Transaction No. HSR-20250328-4192). The filing fee of $2,390,000 was paid by Ardent Apex Holdings Inc. as the acquiring person. On April 2, 2025, the filing was cleared to the FTC by the DOJ pursuant to the interagency clearance process. The initial 30-day waiting period under the HSR Act expires on April 27, 2025.
Anticipated Second Request. Based on the competitive overlap described in this memorandum, as well as preliminary staff inquiries that the FTC has directed to both parties since the filing, we anticipate that the FTC will issue a Second Request on or about April 25, 2025, prior to the expiration of the initial waiting period. Issuance of a Second Request would extend the HSR waiting period until 30 days after both parties have substantially complied with the request. In practice, Second Request compliance typically takes 2–4 months, and the post-compliance waiting period may be extended by agreement with FTC staff through a timing agreement.
Outside Date and extensions. The Merger Agreement establishes an Outside Date of September 10, 2025 — approximately six months from the date of signing. If, as of the Outside Date, the sole unsatisfied closing condition is the receipt of regulatory approval (including expiration or early termination of the HSR waiting period and any required foreign competition clearances), either party may extend the Outside Date by up to three months, to December 10, 2025. This extension mechanism provides a total maximum period of approximately nine months from signing for regulatory clearance.
Reverse termination fee. If Buyer fails to close the Transaction due to a financing failure or willful breach of the Merger Agreement, Buyer is obligated to pay a reverse termination fee ("RTF") of $140,000,000, representing 5.0% of the aggregate deal value. The RTF is the Sellers' sole and exclusive remedy in such a scenario. Importantly, however, the mere failure to obtain regulatory approval does not, by itself, trigger the RTF unless the failure is attributable to Buyer's willful breach of its regulatory efforts covenant.
Regulatory efforts covenant. The Merger Agreement imposes a "reasonable best efforts" obligation on Buyer to obtain all required regulatory approvals, including FTC clearance. This covenant requires Buyer to propose, negotiate, and agree to remedies reasonably necessary to obtain clearance, provided that such remedies do not constitute a "Burdensome Condition." The definition of "Burdensome Condition" in the Merger Agreement is a critical provision that we analyze in detail in Section V below. Notably, the Merger Agreement does not contain a "hell or high water" covenant — Buyer is not obligated to accept any and all remedies demanded by the FTC regardless of their impact on the transaction or Ardent's broader portfolio.
Additional regulatory filings. In addition to the HSR filing, the Transaction requires pre-merger notifications or filings in several additional jurisdictions, including Switzerland (Swiss FINMA/SECO, File No. 32-0973, filed April 7, 2025), Germany (Bundeskartellamt, File No. B6-34/25, filed April 9, 2025), and the EU (Foreign Subsidies Regulation filing, Case No. FSR.M.2025-0412, filed April 11, 2025). A voluntary CFIUS filing was submitted on April 4, 2025 (Tracking No. CFIUS-2025-0087). The Vectis competitive overlap may implicate the German and Swiss filings in addition to the HSR filing, which is discussed further in Section VII below.
III. FTC Analytical Framework
A. Substantive Standard
The FTC's authority to challenge the Transaction derives from Section 7 of the Clayton Act (15 U.S.C. § 18), which prohibits acquisitions where "the effect of such acquisition may be substantially to lessen competition, or to tend to create a monopoly" in any relevant market. Section 7 is an incipiency statute — it is designed to arrest anticompetitive trends in their early stages, before actual competitive harm materializes. The FTC bears the initial burden of establishing a prima facie case that the Transaction is likely to substantially lessen competition, after which the burden shifts to the merging parties to rebut the presumption with evidence of efficiencies, ease of entry, or other procompetitive justifications.
The 2023 FTC/DOJ Merger Guidelines (the "Merger Guidelines"), issued on December 18, 2023, set forth the analytical framework the agencies apply in evaluating mergers. The Merger Guidelines identify several "guidelines" (previously referred to as "presumptions") that inform the agencies' enforcement decisions. The most relevant guidelines for this Transaction are:
1.  Guideline 1 — Market Concentration. Mergers should not significantly increase concentration in highly concentrated markets. A market is "highly concentrated" where the post-merger HHI exceeds 1,800. A merger "significantly increases concentration" where the change in HHI exceeds 100. As noted above, the post-merger HHI in the procurement-automation SaaS market is estimated at approximately 1,532, which falls below the 1,800 threshold. However, the ΔHHI of approximately 252 substantially exceeds the 100-point change threshold. While this means the Transaction may not trigger the formal structural presumption, the substantial increase in concentration will invite close FTC scrutiny.
2.  Guideline 2 — Head-to-Head Competition. Mergers should not eliminate substantial competition between firms. This guideline focuses on direct competitive rivalry between the merging parties. The FTC will examine whether Luminex and Vectis compete head-to-head for the same procurement-automation SaaS customers and whether the elimination of that competition would harm customers. Evidence of direct competition — including win/loss data, customer switching patterns, and internal strategy documents referencing each firm as a competitor — will be central to this analysis.
3.  Guideline 7 — Serial Acquisitions and Industry Roll-Ups. The 2023 Merger Guidelines introduced a new guideline specifically addressing patterns of serial acquisitions. The FTC will evaluate whether the Transaction, viewed in the context of Ardent's existing ownership of Vectis, is part of a pattern of acquisitions that individually or collectively may substantially lessen competition. This guideline is particularly relevant here because the Transaction involves a private equity sponsor acquiring a second significant player in the same market where it already holds a portfolio company.
In light of these guidelines, the FTC is likely to focus its investigation on the following evidentiary areas: (i) direct head-to-head competition between Luminex and Vectis for the same enterprise procurement-SaaS customers, including analysis of competitive bidding situations where both firms participated; (ii) win/loss data maintained by both companies, showing instances where customers chose Luminex over Vectis or vice versa; (iii) customer testimony regarding the competitive significance of Vectis as an alternative to Luminex and the potential impact of common ownership; and (iv) internal strategy documents from both Luminex and Vectis referencing each other as competitors, including market analyses, competitive positioning presentations, and pricing strategy documents.
B. Cross-Ownership / Common-Control Theory
A critical dimension of the FTC's analysis will be its increasingly aggressive focus on private equity cross-ownership and common-control in technology and software markets. The FTC has signaled — through public statements by the Chair and Commissioners, enforcement actions, and revisions to the HSR notification rules — that it views private equity roll-up strategies as a priority enforcement area.
The common-control theory applicable here is straightforward: Although Fund III (which is acquiring Luminex) and Fund II (which holds Vectis) are technically separate fund vehicles with distinct limited partnership agreements, separate investor bases, and separate capital accounts, the FTC will focus on the fact that both funds are ultimately controlled by the same general partner entities and the same managing partners. Specifically:
•  Ardent Capital GP III LLC is the general partner of Fund III and controls the investment and governance decisions of the fund. Its managing members are Theodore "Ted" Hargrove and Victoria Langford.
•  Ardent Capital GP II LLC is the general partner of Fund II and exercises the same control over Fund II's investment and governance decisions. Its managing members are likewise Ted Hargrove and Victoria Langford.
•  The Investment Committee of Fund III consists of Ted Hargrove, Victoria Langford, Marcus Ellison, Priya Chandrasekaran, and David Ng. Based on available information, the Investment Committee of Fund II has the same or substantially overlapping membership.
Under these circumstances, the FTC will argue that post-closing, the same group of individuals — acting through Ardent's general partner and investment committee structures — would have the ability and incentive to coordinate the competitive strategies of both Luminex and Vectis, effectively eliminating the competitive tension between the two platforms. This is true even if Luminex and Vectis are maintained as operationally independent companies with separate management teams, because the ultimate investment and strategic decisions (including pricing strategy, product development priorities, customer targeting, and capital allocation) would be made or ratified by the same decision-makers.
The FTC's position on this point is supported by the economic literature on common ownership and by the Commission's own enforcement precedents. In several recent matters involving private equity acquisitions in healthcare, veterinary services, and enterprise software, the FTC has expressly rejected arguments that separate fund structures or separate management teams are sufficient to eliminate competitive concerns where the sponsor exercises common control over portfolio companies in the same market.
C. Efficiencies Defense
The merging parties may advance several procompetitive arguments in defense of the Transaction:
1.  Distinct customer segments. Luminex and Vectis serve largely different customer populations. Luminex One is primarily marketed to large enterprise customers, particularly multinational corporations with complex, cross-border procurement and supply-chain operations. Its strongest market presence is in the DACH region and among Fortune 500 companies. Vectis, by contrast, is a mid-market-focused solution predominantly serving U.S.-based companies with annual revenues of $100 million to $2 billion. The degree of customer overlap may be limited, and the FTC's concern about elimination of head-to-head competition may be overstated if the two products compete for different customer segments.
2.  Product differentiation. Luminex One is a full-suite ERP/procurement/supply-chain platform, while Vectis is a point solution focused exclusively on procurement automation. From a product-architecture standpoint, these are fundamentally different offerings. Customers selecting Luminex One are typically seeking a comprehensive, integrated enterprise platform, while customers selecting Vectis are typically seeking a best-of-breed procurement tool to complement an existing ERP system. The competitive dynamics between these two product categories are different from competition between two similar point solutions or two similar suite products.
3.  Acquisition-specific efficiencies. Ardent's acquisition of Luminex is expected to generate acquisition-specific efficiencies through the combination of Luminex's platform capabilities with Ardent's operational expertise in scaling enterprise SaaS businesses. These efficiencies — including investments in product development, expansion into new geographic markets, and operational improvements — are not achievable absent the Transaction and would benefit customers through improved product quality and accelerated innovation.
4.  Substantial remaining competition. Even at a combined market share of approximately 25%, the post-merger market would remain competitive, with at least five other significant players (Westmark Partners LLC, Meridian Corporation, Ostrander Industries, Halcyon Holdings, and Cobalt Ridge Holdings) collectively holding approximately 62% of the market. No single firm would dominate the market, and customers would retain meaningful competitive alternatives.
Challenges with the efficiencies defense. Notwithstanding the foregoing arguments, we must candidly assess the limitations of the efficiencies defense in the current enforcement environment. The FTC has been skeptical of claimed efficiencies in recent enforcement actions, consistently noting that efficiencies are difficult to verify, often overstated by merging parties, and frequently not merger-specific. The burden of proof rests squarely on the parties to demonstrate that claimed efficiencies are (i) merger-specific (not achievable through means other than the Transaction), (ii) verifiable (supported by credible evidence rather than speculative projections), and (iii) cognizable (not premised on anticompetitive reductions in output or quality). Additionally, it is inherently difficult to argue that a combined share of approximately 25% — placing the merged entity as the second-largest player in the market — is not competitively significant, particularly when the ΔHHI exceeds 250 points.
IV. Remedy Scenario Analysis
We have identified and evaluated three principal remedy scenarios that may be pursued to resolve the FTC's competitive concerns. Each scenario is analyzed below in terms of its description, feasibility, financial implications, advantages, and disadvantages.
A. Scenario 1: Full Divestiture of Vectis Solutions LLC
1. Description.  Under this scenario, Ardent would sell 100% of its equity interest in Vectis Solutions LLC — held by Ardent Capital Partners II LP (Fund II) — to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition. The divestiture would encompass all of the assets of the Vectis business as a going concern, including:
•  The Vectis procurement-automation SaaS platform, including all associated source code, object code, databases, algorithms, machine-learning models, and related technical documentation;
•  All customer contracts, including subscription agreements, master services agreements, and statements of work;
•  All employees, including the executive management team led by CEO Michael Parekh, as well as engineering, sales, marketing, customer success, and general and administrative personnel;
•  Vectis GmbH, the German subsidiary, together with all of its assets, employees, and customer relationships;
•  All intellectual property, including patents, patent applications, trademarks, trade secrets, copyrights, and domain names;
•  All goodwill associated with the Vectis business; and
•  All other tangible and intangible assets necessary for the operation of Vectis as a viable, independent, competitive business.
Michael Parekh and the Vectis management team would transfer to the purchaser as part of the going-concern sale, or alternatively would be subject to transition services arrangements to ensure business continuity during the ownership transition. In a typical FTC consent decree context, the Commission strongly prefers that key management personnel transfer with the divested business to preserve competitive viability.
2. Estimated Valuation and Financial Impact
The financial implications of a full Vectis divestiture are summarized as follows:
Vectis valuation. Vectis generated total revenue of $68,000,000 in fiscal year 2024. Applying comparable enterprise-value-to-revenue multiples for procurement-SaaS companies, which generally range from approximately 4.0x to 6.0x revenue based on recent transaction precedents and public-company trading comparables, the indicative enterprise value range for Vectis is:
The applicable multiple within this range will depend on Vectis's growth rate, customer retention metrics (net revenue retention, gross churn), profitability profile, competitive positioning, and the specific circumstances of the sale process (including the compressed timeline and regulatory-compulsion context, which may exert downward pressure on the achievable valuation).
Impact on Ardent Fund II returns. A full divestiture of Vectis would result in the loss of future upside potential on the Vectis investment for Fund II's limited partners. This loss would be partially offset by the sale proceeds received, which would be distributed to Fund II LPs in accordance with the Fund II limited partnership agreement. The tax implications of the disposition — including the potential for capital gains treatment, the impact on the fund's carried interest waterfall, and any state and local tax considerations — should be analyzed by Sylvia Hartwell and Pendleton & Associates LLP (contact: Richard Chow).
No impact on Luminex acquisition. Because Vectis is held by Fund II (not Fund III), the divestiture of Vectis has no direct financial impact on the Luminex acquisition's sources and uses. The $2,800,000,000 aggregate deal value for Luminex remains unchanged, and the financing commitments for the Luminex transaction are unaffected. However, Ardent's Fund II LPs and the GP's fiduciary obligations to those LPs are directly implicated, as discussed further below.
3. Process Considerations
FTC consent decree requirements. In a typical FTC consent decree involving a divestiture remedy, the Commission imposes detailed requirements designed to ensure that the divested business remains a viable and effective competitor in the relevant market. These requirements typically include:
•  The purchaser must have the financial capability to operate and invest in the divested business on an ongoing basis;
•  The purchaser must have industry expertise or a credible plan for acquiring the necessary expertise to compete effectively in the procurement-SaaS market;
•  The purchaser must be independent of the divesting party — i.e., the purchaser cannot be an Ardent affiliate, co-investor, or entity that would maintain any economic or governance connection to Ardent;
•  The divestiture must include all assets necessary for the purchaser to operate the business as a going concern, without reliance on transitional support from the divesting party except for a limited, time-bounded transition services period; and
•  The FTC may require the appointment of an interim monitor or divestiture trustee to oversee the sale process and ensure compliance with the consent decree terms.
Upfront buyer requirement. Given the current FTC's preference for certainty of execution, the Commission may require an "upfront buyer" — meaning that the identity of the purchaser must be identified and approved by the FTC before the consent decree is finalized. This approach provides the FTC with assurance that the divestiture will be completed to a qualified buyer, rather than leaving the outcome of the sale process uncertain. If an upfront buyer is required, Ardent would need to conduct a pre-signing marketing process for Vectis in parallel with the FTC investigation, adding complexity to the overall timeline.
Timeline considerations. If the FTC issues a Second Request on or about April 25, 2025, the typical investigation period — including compliance with the Second Request, FTC staff review of the produced documents and data, depositions, and staff recommendation — may take 6 to 12 months. Consent decree negotiations, if the parties and the FTC reach agreement on a divestiture remedy, often occur in parallel with the later stages of the investigation and can add an additional 2 to 3 months. Based on this timeline, it is feasible that the Luminex closing could occur by approximately August to October 2025, assuming the FTC investigation is managed efficiently and consent decree negotiations proceed in good faith.
However, if the Vectis divestiture process is complex or if identifying an FTC-approved buyer takes longer than expected, the timeline could extend beyond the September 10, 2025 Outside Date. In that event, the parties would need to invoke the three-month regulatory extension provision in the Merger Agreement, extending the Outside Date to December 10, 2025.
Conflict of interest considerations. Calderwood & Harkness has represented Vectis Solutions LLC in other matters, and a conflict waiver letter has been executed to address the potential divergence of interests between Vectis and Fund III in a divestiture scenario. Notwithstanding the waiver, if a Vectis divestiture becomes necessary, Calderwood & Harkness should not serve as divestiture counsel for Vectis (i.e., representing Vectis as the seller in the sale process). Vectis and/or Fund II should retain independent outside counsel for the divestiture transaction to avoid the creation of additional conflicts of interest. This issue is discussed further in Section VI below.
4. Advantages.  
•  Cleanest remedy. A full Vectis divestiture eliminates the competitive overlap entirely. There is no residual issue of common ownership in the procurement-automation SaaS market, and no ongoing compliance obligations or monitoring requirements.
•  Most likely to satisfy FTC quickly. Given the FTC's strong preference for structural remedies and its skepticism of behavioral alternatives, a full Vectis divestiture is the remedy most likely to secure prompt FTC acceptance and avoid protracted negotiation or litigation.
•  Preserves full strategic value of Luminex acquisition. The $2.8 billion Luminex acquisition — the centerpiece of Ardent Fund III's investment strategy — proceeds unimpaired. No carve-outs, restrictions, or modifications to the Luminex business are required.
•  Avoids risk of protracted FTC litigation. If the FTC determines that the overlap is competitively significant and the parties are unable to agree on a remedy, the Commission may seek a preliminary injunction in federal court to block the Transaction. FTC litigation is costly, time-consuming, and uncertain in outcome. A Vectis divestiture moots the competitive concern and eliminates the litigation risk.
5. Disadvantages.  
•  Loss of a valuable portfolio asset for Fund II. Vectis is a high-growth procurement-SaaS business with substantial value. A forced divestiture deprives Fund II's limited partners of the future upside potential of the investment, including the possibility that Vectis could be grown and eventually sold or taken public at a higher valuation.
•  Potential fire-sale discount. If the Vectis sale is conducted under regulatory compulsion with a compressed timeline, potential buyers may exploit the circumstances to negotiate a lower purchase price. The FTC's requirement that the buyer be pre-approved and the consent decree's deadline for completion of the divestiture may further limit Ardent's negotiating leverage.
•  Management resistance. Michael Parekh and the Vectis management team may resist the divestiture or seek enhanced financial terms (e.g., accelerated vesting of equity incentives, retention bonuses, or enhanced severance protections) as a condition of their cooperation. Management resistance could slow the process and complicate the sale.
•  Fund II LPA considerations. Depending on the terms of the Fund II limited partnership agreement, a disposition of a significant portfolio company may require approval from the LP advisory committee or may trigger other governance requirements. Ardent Capital GP II LLC, as the general partner of Fund II, owes fiduciary duties to the Fund II limited partners, and a decision to divest Vectis in order to facilitate a Fund III transaction raises inherent conflicts of interest that must be carefully managed. We recommend consulting with Ardent's GP counsel on these issues.
B. Scenario 2: Partial Divestiture — Carve-Out of Overlapping Product Lines or Customer Segments
1. Description.  Under this scenario, rather than divesting Vectis in its entirety, Ardent would divest only the specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap with the other company's offerings. This approach seeks to preserve maximum value across both portfolio companies while addressing the FTC's competitive concerns in a targeted manner. We have identified two principal sub-options:
•  Option 2A — Carve out Luminex's procurement module. Luminex's stand-alone procurement-automation module would be separated from the Luminex One platform and divested to a third-party purchaser. The purchaser would receive the procurement module's code base, related intellectual property, and potentially a subset of Luminex's procurement-focused customer contracts. The remaining components of Luminex One (ERP, supply-chain analytics, contract lifecycle management) would be retained by Ardent.
•  Option 2B — Carve out a subset of Vectis's enterprise customers. A subset of Vectis's customer base — specifically, the enterprise-tier customers whose procurement needs most directly overlap with Luminex's offerings — would be separated from the Vectis business and divested to a third party, together with the associated customer contracts, account management personnel, and a license to the Vectis platform. Vectis would retain its mid-market customer base and continue to operate as an Ardent Fund II portfolio company.
2. Feasibility Assessment
Option 2A — Luminex procurement module carve-out. This option presents formidable technical and commercial challenges. The procurement-automation functionality within Luminex One is deeply integrated into the platform's architecture. The procurement module shares a common data model, user interface framework, authentication and security infrastructure, and application programming interfaces (APIs) with the other components of Luminex One. Separating the procurement module into a stand-alone product would require significant re-engineering effort, potentially taking 12 to 18 months or longer. Moreover, the carved-out procurement module would likely not be a commercially viable stand-alone business, as it was designed to function as part of an integrated suite and lacks the independent go-to-market infrastructure (sales team, marketing, customer support) to compete effectively on its own.
From a regulatory perspective, the FTC is unlikely to accept a partial divestiture that results in a non-viable stand-alone business. The Commission's consent decree standards require that the divested assets be sufficient to enable the purchaser to compete effectively in the relevant market. A carved-out Luminex procurement module that cannot function independently, or that requires extensive re-engineering before it can be deployed by customers, would not satisfy this standard.
We do not recommend Option 2A.
Option 2B — Vectis enterprise customer carve-out. This option is more feasible than Option 2A from a technical standpoint, because Vectis is a point solution with a relatively modular architecture, and its customer contracts are structured as individual subscription agreements that can, in principle, be assigned to a third-party purchaser. However, several significant challenges remain:
•  Customer segmentation. The FTC would need to be satisfied that the divested customer segment is the segment that creates the competitive overlap with Luminex. If Vectis's enterprise customers are divested but the remaining mid-market customers continue to overlap with Luminex's customer base (which also includes some mid-market accounts), the FTC may view the partial divestiture as insufficient.
•  Platform viability. The purchaser of Vectis's enterprise customers would need access to the Vectis platform to serve those customers. This would require either (a) a transfer of the Vectis platform code base and IP to the purchaser (which essentially becomes a full divestiture minus the mid-market customer base) or (b) a long-term license of the Vectis platform to the purchaser, which introduces ongoing dependency on Ardent/Vectis and is unlikely to satisfy the FTC's stand-alone viability requirements.
•  Employee transfers. The engineering team that maintains and develops the Vectis platform would likely need to transfer in whole or in part with the divested business, further eroding the value of the retained Vectis mid-market business.
We view Option 2B as theoretically possible but practically challenging and uncertain in terms of FTC acceptance. Significant additional technical due diligence would be required to determine the separability of the code base, data infrastructure, and customer deployments before this option could be developed into a credible remedy proposal.
3. Advantages.  
•  Preserves partial value of both portfolio companies. If executed successfully, a partial divestiture would allow Ardent to retain portions of both the Luminex and Vectis businesses, preserving value for both Fund III and Fund II investors.
•  Targeted remedy. A partial divestiture addresses only the specific area of overlap, rather than requiring a wholesale disposition of an entire portfolio company. This may be viewed as a more proportionate remedy relative to the competitive concern.
4. Disadvantages.  
•  Execution complexity and cost. Carving out product lines or customer segments from an integrated software business requires extensive technical work, including data migration, code separation, transition services agreements, IP licensing arrangements, and employee transfers. These processes are time-consuming, expensive, and prone to error.
•  FTC skepticism. The FTC has historically viewed partial divestitures in technology markets with considerable skepticism, preferring "clean sweep" structural remedies that eliminate any ongoing relationship between the divesting party and the divested business. FTC staff may conclude that a partial divestiture is designed to preserve the parties' commercial interests at the expense of competitive effectiveness.
•  Risk of creating a non-viable asset. If the carved-out business cannot function effectively as a stand-alone entity, it may fail in the market, which would not only harm customers and competition but also invite the FTC to revisit the consent decree and potentially seek additional relief. The risk of "remedy failure" is a significant concern for both the parties and the FTC.
•  Longer negotiation timeline. Negotiating a partial divestiture with FTC staff is inherently more complex than negotiating a full divestiture, because the parties and the FTC must agree on the precise scope of the assets to be divested, the adequacy of transition services, the viability of the stand-alone business, and the qualifications of the purchaser to operate a more narrowly defined business. This extended negotiation timeline increases the risk of exceeding the Outside Date.
•  Residual overlap risk. Depending on how the partial divestiture is structured, the FTC may conclude that the combined share in the remaining product segments or customer categories still exceeds the Commission's competitive-concern thresholds. This is particularly true if the FTC defines the relevant market broadly enough to encompass both the divested and retained segments.
C. Scenario 3: Behavioral / Conduct Remedies
1. Description.  Under this scenario, Ardent would not divest any assets. Instead, it would agree to implement behavioral or conduct-based measures designed to maintain competitive independence between Luminex and Vectis while both remain under common Ardent ownership. The specific behavioral remedies that could be proposed include:
•  Firewall agreements. Ardent would establish formal information barriers between the Luminex and Vectis management and commercial teams. The firewalls would restrict the sharing of competitively sensitive information — including pricing data, customer lists, bid strategies, product roadmaps, and competitive strategy — between the two companies. Ardent investment professionals who interact with both portfolio companies would be subject to protocols governing the handling of competitively sensitive information.
•  Independent management. Vectis would continue to be managed by Michael Parekh as CEO, with independent authority over commercial strategy, pricing, product development, and customer engagement. Ardent investment professionals would be restricted from simultaneously serving on the boards of directors (or equivalent governing bodies) of both Luminex and Vectis. Each company would maintain a separate board with a majority of independent directors.
•  Pricing commitments. Ardent would commit to maintaining independent pricing for the Luminex One procurement modules and the Vectis platform for a specified period (e.g., five to ten years). Neither company would be permitted to coordinate pricing with the other, and pricing decisions would be made independently by each company's management team.
•  Compliance monitoring. Ardent would agree to the appointment of an FTC-designated compliance monitor — an independent third party — to oversee compliance with the behavioral conditions for a defined period (e.g., five to ten years). The monitor would have access to relevant records, personnel, and communications of both Luminex and Vectis, and would report periodically to the FTC on compliance status.
2. FTC Receptiveness
Our assessment of the current FTC's receptiveness to behavioral remedies in this case is highly unfavorable. Several factors support this conclusion:
•  Current FTC leadership strongly disfavors behavioral remedies. The FTC Chair and a majority of the Commissioners have publicly stated — in speeches, policy statements, and written concurrences — that structural remedies (divestitures) are the preferred means of addressing competitive harm in merger cases, and that behavioral remedies are disfavored because they are difficult to design, difficult to monitor, easy to circumvent, and not self-enforcing.
•  Recent enforcement precedents. In virtually all recent FTC consent decrees in technology and software markets, the Commission has required structural remedies. Behavioral-only consent decrees have been exceedingly rare, and where they have been approved, they typically involve situations where a structural remedy was not feasible or where the competitive overlap was de minimis.
•  Common-control theory. The FTC's core concern in this case is that common Ardent ownership of Luminex and Vectis would eliminate the competitive incentive between the two companies. Behavioral remedies such as firewalls and independent management do not address this fundamental concern. Even with robust firewalls in place, the FTC will argue that the same individuals (Ted Hargrove, Victoria Langford, and their Investment Committee colleagues) will ultimately make the strategic decisions for both companies, and that the economic incentive to coordinate rather than compete will inevitably prevail over paper-based compliance measures.
•  Availability of a structural alternative. The FTC is particularly unlikely to accept behavioral remedies where a clean structural remedy is readily available. Vectis is a discrete, going-concern business that can be sold in its entirety to an independent purchaser. The FTC will view a behavioral-remedy proposal as an attempt to avoid the obvious structural solution and will likely reject it out of hand.
Assessment: We assign a very low probability — less than 10% — that the FTC would accept a behavioral-only remedy in this case.
3. Advantages.  
•  No asset disposition required. Ardent retains ownership of both Luminex and Vectis, preserving the investment thesis for both Fund III and Fund II.
•  Preserves fund economics. Both Fund II (Vectis) and Fund III (Luminex) achieve their target returns without the dilution caused by a forced divestiture at a potentially suboptimal valuation.
4. Disadvantages.  
•  FTC highly unlikely to accept. As discussed above, the current enforcement environment makes FTC acceptance of behavioral-only remedies exceedingly improbable in this case.
•  Ongoing compliance burdens. Even if behavioral remedies were accepted, they would impose significant ongoing compliance costs and operational burdens on Ardent, Luminex, and Vectis for the duration of the consent decree (potentially five to ten years or longer).
•  Monitoring costs. The costs of the FTC-appointed compliance monitor — including the monitor's fees, expenses, and the internal resources required to support the monitor's oversight activities — would be borne by the parties.
•  Does not address fundamental concern. Behavioral remedies do not address the FTC's core concern about common-control incentives. The Commission will view firewalls and independent management protocols as temporary and inherently unreliable safeguards that do not change the underlying economic incentives of common ownership.
•  Strategic signaling risk. Offering behavioral-only remedies early in the FTC negotiation process could signal to FTC staff that the parties lack confidence in their substantive defense and are eager to reach a settlement at any cost. This could embolden FTC staff to push for broader structural relief — potentially extending beyond the Vectis overlap to other aspects of the Transaction. We strongly recommend that any behavioral-remedy proposal be offered only as a fallback or supplement to a structural remedy, and only in the context of a carefully negotiated consent decree.
V. Impact on Merger Agreement Provisions
A. Regulatory Efforts Covenant
The Merger Agreement imposes a "reasonable best efforts" obligation on Buyer (Ardent Apex Holdings Inc.) to obtain all required governmental and regulatory approvals, including FTC clearance under the HSR Act. This covenant is set forth in Section 6.04 of the Merger Agreement and requires Buyer to take commercially reasonable actions to obtain clearance, including:
•  Filing all required notifications and applications with governmental authorities in a timely manner;
•  Cooperating with FTC staff during the review process, including responding to informal inquiries, producing documents and data pursuant to any Second Request, and making witnesses available for depositions and interviews;
•  Proposing, negotiating, and agreeing to remedies reasonably necessary to obtain FTC clearance, provided that such remedies do not constitute a "Burdensome Condition" (as defined in the Merger Agreement); and
•  Not taking any action that would reasonably be expected to materially delay or impair the prospects of obtaining FTC clearance.
The "Burdensome Condition" definition is the critical limitation on Buyer's obligations. While we have not reproduced the full contractual text here (see Appendix B for relevant excerpts), the definition is generally understood to encompass any remedy, condition, or undertaking that would:
(a) Require the divestiture, license, or other disposition of assets, businesses, or product lines of Luminex or any of its subsidiaries generating aggregate annual revenues in excess of a specified dollar threshold;
(b) Impose restrictions on the post-closing operations or business conduct of Luminex or any of its subsidiaries that would materially impair the strategic rationale for the Transaction or materially diminish the expected financial returns; or
(c) Otherwise require Buyer or any of its affiliates to take actions that are materially disproportionate to the competitive concern being addressed.
Analysis — Would a full Vectis divestiture constitute a "Burdensome Condition"? In our assessment, the answer is likely no, for the following reasons:
First, the Burdensome Condition definition, as typically drafted in private equity acquisition agreements, is focused on divestitures or restrictions affecting the acquired business — i.e., Luminex and its subsidiaries. A divestiture of Vectis, which is a separate portfolio company held by a separate fund (Fund II), does not involve the disposition of any Luminex assets and does not impose any restriction on Luminex's post-closing operations. Accordingly, a Vectis divestiture likely falls outside the scope of the Burdensome Condition definition.
Second, the Burdensome Condition carve-out is designed to protect Buyer against being compelled to sacrifice the economic value of the acquisition itself — not to insulate Buyer from any regulatory burden that may affect its broader portfolio. The divestiture of a $272 million to $408 million Fund II asset to facilitate the closing of a $2.8 billion Fund III acquisition is not, on its face, disproportionate.
However, there is an important nuance: While a Vectis divestiture may not constitute a "Burdensome Condition" under the Merger Agreement, Ardent's willingness to divest a Fund II asset to close a Fund III deal raises separate fiduciary duty concerns. Ardent Capital GP II LLC owes fiduciary duties to the limited partners of Fund II, and a decision to divest Vectis — potentially at a discounted price and on a compressed timeline — in order to benefit a separate fund raises inherent conflicts of interest. These conflicts must be managed through appropriate governance processes, including LP advisory committee consultation and, potentially, independent counsel for the Fund II GP.
B. Outside Date and Extension
The Merger Agreement establishes an Outside Date of September 10, 2025, approximately six months from the date of signing (March 24, 2025). If, as of the Outside Date, the sole unsatisfied closing condition is the receipt of regulatory approval (including expiration or early termination of the HSR waiting period and any required foreign regulatory clearances), either

PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT

INTERNAL MEMORANDUM

Record

Parties

Dates

Amounts